Anti-GLP-1 antibody [4F3] (ab23472)
Key features and details
- Mouse monoclonal [4F3] to GLP-1
- Suitable for: IHC-P, ELISA
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-GLP-1 antibody [4F3]
See all GLP-1 primary antibodies -
Description
Mouse monoclonal [4F3] to GLP-1 -
Host species
Mouse -
Specificity
Reacts with all forms of GLP1, including precursor and GLP1(9-37) /GLP1(9-36amide) metabolite. ab23472 cross-reacts with Liraglutide. -
Tested applications
Suitable for: IHC-P, ELISAmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mammals -
Immunogen
Synthetic peptide within Human GLP-1 aa 1 to the C-terminus. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P01275 -
Epitope
Mid molecular epitope of GLP1. -
Positive control
- IHC-P: Human pancreas tissue
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.097% Sodium azide
Constituents: 0.0268% PBS, 2.9% Sodium chloride -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
4F3 -
Myeloma
x63-Ag8.653 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
sELISA pair antibody
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab23472 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/1000.
|
|
ELISA |
Use at an assay dependent concentration. PubMed: 29953011
|
Notes |
---|
IHC-P
1/1000. |
ELISA
Use at an assay dependent concentration. PubMed: 29953011 |
Target
-
Function
Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.
GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.
GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.
Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.
Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. -
Tissue specificity
Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP1 and GLP2 are also secreted in selected neurons in the brain. -
Sequence similarities
Belongs to the glucagon family. -
Post-translational
modificationsProglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 2641 Human
- Omim: 138030 Human
- SwissProt: P01275 Human
- Unigene: 516494 Human
-
Alternative names
- GCG antibody
- Glicentin related polypeptide antibody
- glicentin-related polypeptide antibody
see all
Images
-
ab23472 (1µg/ml) staining GLP-1 in human pancreas, using an automated system (DAKO Autostainer Plus). Using this protocol there is strong cytoplasmic staining.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer citrate pH6.1 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (9)
ab23472 has been referenced in 9 publications.
- Fujiwara Y et al. Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids. Am J Physiol Gastrointest Liver Physiol 320:G617-G626 (2021). PubMed: 33533304
- Lang S et al. Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice. Peptides 131:170349 (2020). PubMed: 32561493
- Zhang X et al. Fructose malabsorption induces cholecystokinin expression in the ileum and cecum by changing microbiota composition and metabolism. FASEB J 33:7126-7142 (2019). PubMed: 30939042
- Weng S et al. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore) 97:e11293 (2018). PubMed: 29953011
- Xu F et al. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS One 12:e0181939 (2017). PubMed: 28750064
- Okita N et al. Modified Western blotting for insulin and other diabetes-associated peptide hormones. Sci Rep 7:6949 (2017). PubMed: 28761041
- Jiang S et al. AMPK-dependent regulation of GLP1 expression in L-like cells. J Mol Endocrinol 57:151-60 (2016). PubMed: 27493247
- Marchetti P et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262-72 (2012). PubMed: 22965295
- Fishbein TM et al. Rejection reversibly alters enteroendocrine cell renewal in the transplanted small intestine. Am J Transplant 9:1620-8 (2009). WB ; Human . PubMed: 19519821